Sami Alsuwaidan,Tala A Qadoumi,Reem Alsergani et al.
Sami Alsuwaidan et al.
Introduction: Infantile hemangiomas are common and can be treated with propranolol. Cardiovascular side effects are a potential risk of propranolol treatment. We assessed real-world propranolol side effects to help guide ...
Sustained on/off-treatment disease control with abrocitinib for moderate-to-severe atopic dermatitis [0.03%]
阿布昔替尼对中重度特应性皮炎的持续良好疗效：中断治疗后的疾病反弹及再次起效
Emma Guttman-Yassky,Thomas Bieber,Kenji Kabashima et al.
Emma Guttman-Yassky et al.
Purpose: Achieving sustained on- and off-treatment disease control is an important therapeutic goal in atopic dermatitis (AD). This study evaluated achievement of off-treatment disease control in patients randomized to pl...
Patient preferences for treatment characteristics of Janus kinase inhibitors for alopecia areata: a discrete choice experiment [0.03%]
脱发性均天 kinase抑制剂治疗特征的患者偏好：一项离散选择实验
Natasha Mesinkovska,Arash Mostaghimi,Kathleen L Deering et al.
Natasha Mesinkovska et al.
Background: Janus kinase inhibitors (JAKis) can improve hair regrowth in alopecia areata (AA). Objective: This study examined which tre...
Long-term benefits of upadacitinib for Atopic Dermatitis: deep responses in patient-reported outcomes over 140 weeks from the Measure Up 1 and Measure Up 2 clinical trials [0.03%]
Upadacitinib治疗特应性皮炎的长期效益：来自Measure Up 1和Measure Up 2临床试验长达140周研究中的患者报告结果达到深度缓解
Eric L Simpson,Vimal H Prajapati,Christopher G Bunick et al.
Eric L Simpson et al.
Objectives: Atopic dermatitis (AD), a chronic, immune-mediated inflammatory disease, is characterized by intense itch, eczematous rash, and skin pain, which can have negative impacts to quality-of-life (QoL), sleep, and m...
Beyond efficacy: pulse duration is crucial for adverse events in pulsed dye laser therapy for rosacea [0.03%]
疗效之外：激光治疗玫瑰痤疮的不良反应与脉冲宽度密切相关
Tingwei Liu,Yurong Liu,Xiaoqi Meng et al.
Tingwei Liu et al.
Background: Pulsed dye laser (PDL) is widely used for erythematotelangiectatic rosacea (ETR); however, the influence of pulse duration remains unclear. Ob...
Randomized Controlled Trial
The Journal of dermatological treatment. 2026 Dec;37(1):2665064. DOI:10.1080/09546634.2026.2665064 2026
Distinct ocular safety profiles of dupilumab and upadacitinib in atopic dermatitis: a real-world study with ophthalmological and microbiological assessment [0.03%]
Dupixent和Upadacitinib治疗特应性皮炎不同的眼部安全性特征：一项结合眼科及微生物学评估的现实世界研究
Paulina Stepinska,Kamila Zawadzinska-Halat,Maciej Pastuszczak
Paulina Stepinska
Background: Dupilumab is highly effective in atopic dermatitis (AD) but is associated with ocular surface disease, whereas Janus kinase (JAK) inhibitors may have a more favorable ocular safety profile. ...
Complete clearance of high-impact sites with risankizumab in patients with psoriasis: a 2-year real-world retrospective multicenter cohort study [0.03%]
利西纳珠单抗治疗银屑病患者高炎症部位完全清除的长期疗效：一项为期两年的真实世界多中心队列研究
Margarida Contente,Ana Luísa João,Martim Luz et al.
Margarida Contente et al.
Objectives: Plaque psoriasis frequently involves high-impact anatomical sites such as the scalp, nails, and palmoplantar regions, which are associated with significant functional impairment and reduced quality of life. Ev...
Recalcitrant tinea infections due to Trichophyton indotineae in the United States (2025-2026): a retrospective case series identified by real-time PCR [0.03%]
美国（2025-2026年）由实时PCR鉴定的顽固性表皮葡萄球菌感染：病例系列回顾研究
Aditya K Gupta,Tong Wang,Sara A Lincoln et al.
Aditya K Gupta et al.
Trichophyton indotineae is an emerging dermatophytic pathogen causing severe infections that are frequently resistant to standard antifungals. Since 2015, this species has spread intercontinentally. ...
Progressive alopecia areata during TNF-α inhibition with intralesional corticosteroid failure and subsequent improvement following JAK1 inhibition [0.03%]
肿瘤坏死因子抑制治疗过程中出现进行性红斑狼疮脱发、局部皮质类固醇治疗无效及口服JAK1抑制剂后病情改善的一例报告
Mandisi Brendon Nkala,Firouzeh Niakosari
Mandisi Brendon Nkala
Objectives: To report a case of AA developing during golimumab and leflunomide treatment for seropositive rheumatoid arthritis, with subsequent improvement following initiation of selective Janus kinase 1 (JAK1) inhibitio...